Citigroup’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.7M Buy
77,000
+37,000
+93% +$5.18M ﹤0.01% 1429
2025
Q4
$4.91M Hold
40,000
﹤0.01% 2021
2025
Q3
$4.44M Hold
40,000
﹤0.01% 2053
2025
Q2
$4.43M Sell
40,000
-97,700
-71% -$10.4M ﹤0.01% 1994
2025
Q1
$15.4M Sell
137,700
-40,000
-23% -$4.13M 0.01% 1106
2024
Q4
$16.4M Sell
177,700
-104,900
-37% -$9.44M 0.01% 1068
2024
Q3
$23.7M Sell
282,600
-97,600
-26% -$7.45M 0.01% 859
2024
Q2
$26.1M Buy
380,200
+168,200
+79% +$11.2M 0.02% 778
2024
Q1
$15.5M Buy
212,000
+1,200
+0.6% +$92.3K 0.01% 1014
2023
Q4
$17.1M Sell
210,800
-21,000
-9% -$1.63M 0.01% 943
2023
Q3
$17.4M Buy
231,800
+70,800
+44% +$5.45M 0.01% 843
2023
Q2
$12.4M Buy
161,000
+20,000
+14% +$1.6M 0.01% 1042
2023
Q1
$11.7M Buy
141,000
+30,000
+27% +$2.48M 0.01% 1084
2022
Q4
$9.53M Sell
111,000
-421,700
-79% -$33.4M 0.01% 1159
2022
Q3
$32.9M Buy
532,700
+111,100
+26% +$7.01M 0.02% 543
2022
Q2
$26.1M Buy
421,600
+213,400
+102% +$13.2M 0.02% 673
2022
Q1
$12.4M Sell
208,200
-1,335,500
-87% -$85.4M 0.01% 1187
2021
Q4
$112M Buy
1,543,700
+35,000
+2% +$2.41M 0.06% 285
2021
Q3
$105M Buy
1,508,700
+130,000
+9% +$9.13M 0.06% 276
2021
Q2
$94.9M Sell
1,378,700
-407,100
-23% -$27.2M 0.06% 311
2021
Q1
$115M Sell
1,785,800
-211,100
-11% -$13.6M 0.07% 242
2020
Q4
$116M Buy
1,996,900
+434,600
+28% +$26.2M 0.07% 259
2020
Q3
$98.7M Buy
1,562,300
+53,900
+4% +$3.74M 0.06% 246
2020
Q2
$116M Sell
1,508,400
-303,200
-17% -$23.2M 0.09% 189
2020
Q1
$135M Buy
1,811,600
+1,076,600
+146% +$74.4M 0.12% 138
2019
Q4
$47.8M Buy
735,000
+272,600
+59% +$17.8M 0.03% 528
2019
Q3
$29.3M Sell
462,400
-209,500
-31% -$13.7M 0.02% 708
2019
Q2
$45.4M Buy
671,900
+133,500
+25% +$8.78M 0.04% 480
2019
Q1
$35M Sell
538,400
-235,900
-30% -$15.7M 0.03% 543
2018
Q4
$48.4M Buy
774,300
+89,100
+13% +$6.23M 0.05% 407
2018
Q3
$52.9M Sell
685,200
-99,600
-13% -$7.52M 0.05% 365
2018
Q2
$55.6M Sell
784,800
-417,400
-35% -$29.5M 0.05% 329
2018
Q1
$90.6M Sell
1,202,200
-498,700
-29% -$39.6M 0.07% 218
2017
Q4
$122M Sell
1,700,900
-46,700
-3% -$3.55M 0.1% 188
2017
Q3
$142M Buy
1,747,600
+941,700
+117% +$72M 0.12% 128
2017
Q2
$57M Sell
805,900
-266,300
-25% -$17.7M 0.05% 300
2017
Q1
$72.8M Sell
1,072,200
-198,300
-16% -$13.9M 0.06% 251
2016
Q4
$91M Sell
1,270,500
-382,500
-23% -$28.4M 0.08% 226
2016
Q3
$131M Buy
1,653,000
+362,400
+28% +$29.4M 0.12% 132
2016
Q2
$108M Buy
1,290,600
+532,900
+70% +$47.3M 0.11% 159
2016
Q1
$69.6M Sell
757,700
-1,083,800
-59% -$97.7M 0.08% 235
2015
Q4
$186M Buy
1,841,500
+348,900
+23% +$36.3M 0.19% 86
2015
Q3
$147M Sell
1,492,600
-92,100
-6% -$10.2M 0.14% 109
2015
Q2
$186M Buy
1,584,700
+96,800
+7% +$10.6M 0.16% 86
2015
Q1
$146M Sell
1,487,900
-2,053,600
-58% -$209M 0.14% 114
2014
Q4
$334M Buy
3,541,500
+1,073,600
+44% +$111M 0.3% 33
2014
Q3
$263M Buy
2,467,900
+423,000
+21% +$41.4M 0.23% 51
2014
Q2
$170M Buy
2,044,900
+30,100
+1% +$2.34M 0.16% 95
2014
Q1
$143M Sell
2,014,800
-74,600
-4% -$5.85M 0.15% 105
2013
Q4
$157M Buy
2,089,400
+660,400
+46% +$46M 0.14% 108
2013
Q3
$89.8M Sell
1,429,000
-80,000
-5% -$4.78M 0.08% 211
2013
Q2
$77.3M Buy
+1,509,000
New +$78.7M 0.08% 200

Other funds holding GILD

Citigroup's GILD Position: Q1 2026 in Review

Citigroup increased its Gilead Sciences (GILD) stake by 30% in Q1 2026, buying an estimated $73.4M and bringing the position to 2,300,271 shares worth $321M. The position accounts for 0.14% of the portfolio, ranked #145.

Citigroup first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Citigroup held 2,300,271 shares of Gilead Sciences worth $321M as of Q1 2026.
  • Citigroup bought 524,041 Gilead Sciences shares in Q1 2026, an estimated $73.4M.
  • Gilead Sciences made up 0.14% of Citigroup's portfolio in Q1 2026, its #145 holding.
  • Citigroup first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.